However, it remains unclear whether entrectinib can simultaneously inhibit both tyrosine kinase and the STAMBP protein to further enhance the sensitivity of pancreatic cancer to gemcitabine, which warrants further exploration in the future. Here, STAMBP is linked to pancreatic neoplasm.